宫腔镜与宫颈注射在子宫内膜癌前哨淋巴结检测中的多中心随机对照试验
本研究为多中心前瞻性随机对照试验,纳入165例子宫内膜癌患者,随机分为宫颈注射组(85例)和宫腔镜注射组(80例),最终151例纳入分析。主要终点为腹主动脉旁检出率,结果显示宫腔镜注射腹主动脉旁检出率略高约10%但无统计学差异,而宫颈注射盆腔检出率更高,总体支持采用宫颈注射。
要点
- 宫颈注射组盆腔前哨淋巴结检出率高于宫腔镜注射组。
- 宫腔镜注射组腹主动脉旁检出率略高约10%,但差异无统计学意义。
- 宫腔镜注射组孤立腹主动脉旁前哨淋巴结检出率为5.8%,宫颈注射组为0%。
核心结论
- 本研究支持采用宫颈注射而非宫腔镜注射,因为前者能更好地识别前哨淋巴结,尤其在盆腔区域。
- 宫腔镜注射在腹主动脉旁区域检出前哨淋巴结略高,但与宫颈注射的差异无统计学意义。
研究设计与样本
- 多中心前瞻性随机对照试验,由意大利卵巢癌多中心试验(MITO)研究组开展。
- 纳入组织学确诊的 apparent I或II期子宫内膜癌接受手术患者,按1:1随机分配至宫颈注射或宫腔镜注射组,非盲法。
- 2017年3月至2019年4月共随机165例(宫颈注射组85例,宫腔镜注射组80例),随机后排除14例(8.5%),最终151例纳入分析(宫颈注射组82例,宫腔镜注射组69例)。
主要发现
- 宫腔镜注射检测腹主动脉旁前哨淋巴结的能力比宫颈注射高约10%,但差异未达统计学显著性。
- 宫腔镜注射在检测孤立腹主动脉旁前哨淋巴结方面更优(5.8% 对 0%)。
- 宫颈注射与更高的盆腔前哨淋巴结检出率相关,盆腔和总体检出率在宫颈注射组更高。
临床怎么用
- 对于新诊断子宫内膜癌的手术分期,可优先选择宫颈注射吲哚菁绿进行前哨淋巴结定位。
- 若需重点评估腹主动脉旁区域,宫腔镜注射可能略有优势,但证据未达统计学显著。
局限性
- 本研究未对患者或外科医生设盲。
- 随机后排除14例(8.5%)患者,最终分析151例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: During the last years, the role of sentinel lymph node mapping (SLNM) for endometrial cancer (EC) surgical treatment has increased in popularity. However, several controversies remain about different technical steps of SLNM. Thus, a randomised control trial was designed to compare cervical (CI) and hysteroscopic (HI) indocyanine green (ICG) injection for SLNM of newly diagnosed EC undergoing surgical staging. The primary end-point of the study was to compare these two techniques in terms of para-aortic detection rate. METHODS: Patients with apparent stage I or II histologically confirmed EC undergoing surgery were included in the study. This randomised trial distinguished patients in two study groups according to two different techniques of ICG SLNM: CI versus HI injection. Patients who met the inclusion criteria were randomly assigned to CI or HI injection in a 1:1 ratio. The central randomisation system allocated patient randomisation numbers sequentially in the order in which the patients were enrolled. This randomised trial was not blinded for either patients or the surgeons. RESULTS: From March 2017 until April 2019, a total of 165 patients were randomised in this study: 85 (51.5%) in the CI group and 80 (48.5%) in the HI group. After randomisation, 14 (8.5%) patients were excluded from the study. Finally, 151 patients were included in the analysis: 82 (54.3%) in the CI group and 69 (45.7%) in the HI group. Hysteroscopy injection shows an ability to detect Sentinel nodes (SNLs) in the para-aortic area of about 10% greater compared with CI injection, although this difference did not reach statistical significance. The HI technique was superior in detecting isolated para-aortic SLNs (5.8% Versus 0%). The CI injection was correlated with higher SLN detection rates at the pelvic level compared with HI injection. Pelvic and overall detection was higher in the CI group. CONCLUSIONS: The present study supports the adoption of CI instead of HI injection because the former allows better identification of sentinel nodes (especially in the pelvic area). Detection of SLN in the para-aortic area was slightly higher in patients receiving a HI injection, but the difference with the CI route was not statistically significant.
引用
- Ditto A, Casarin I, Pinelli C, et al. Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group. Eur J Cancer. 2020. PMID: 33027722. doi:10.1016/j.ejca.2020.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。